BIAF$3.13+4.75%
bioAffinity Technologies, Inc.
Sector: Services-Commercial Physical & Biological ResearchIndustry: Medical - Diagnostics & ResearchCountry: USExchange: Nasdaq
Mkt Cap:$4.02M
Float & O/S:
Inst Own:
DilutionScan read 55 of bioAffinity Technologies, Inc.'s SEC filings and found 20 warrant series, 1 convertible, 1 ATM program, 2 shelf registrations, 7 S-1 registrations and 3 completed offerings on file for BIAF. The latest dilution event on file is ATM sales on Nov 2, 2026. Analysis updated Nov 2, 2026.
Signal8 Summary
BIAF
Going-concern warning, severe cash strain
Snapshot
bioAffinity is a tiny diagnostics company selling its CyPath Lung cancer test, with FY2025 revenue of $6.2M, down 34% from a smaller prior-year base, and a net loss of $14.9M.
What's Happening Right Now
- : Nasdaq notified BIAF on July 30, 2026 that it's out of compliance with the $1.00 minimum bid price rule, and because of a prior reverse split the company doesn't get the usual 180-day grace period; it's appealing to a Nasdaq panel.
- : Registered 1.71M shares for sale on Form S-3.
- : BIAF executed a 1-for-15 reverse stock split effective August 24, 2026, primarily to try to regain Nasdaq compliance, leaving about 592,373 shares outstanding post-split.
- : Raised $3.94M in gross proceeds through a private placement (PIPE), with warrants over 1.71M shares.
- : Q2 2026 revenue rose 19% YoY to $1.5M on a 216% jump in CyPath Lung test volume, and the net loss narrowed to $3.4M from $4.1M, though cash stood at just $2.4M after a $3.2M offering.
- : On July 30, 2026, BIAF announced a collaboration with Pictor, Inc. to co-develop diagnostic tests for asthma and COPD, aiming to launch them as lab-developed tests.
- : Sold $1.20M of stock / 8K shares through its at-the-market program.
- : In a June 12, 2026 S-1 filing to raise ~$3.4M, BIAF disclosed only $3.1M in cash and a $72.2M accumulated deficit, and its auditor issued a going-concern warning tied to the company's ability to keep operating without more capital.
